Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842509 | 0.79 | TSHR (0.31) | KDM4EALDH1A1 | |
| SCHEMBL6842488 | 0.78 | LMNA (0.35) | KDM4ELMNACNR1ADRA1ATDP1 | |
| SCHEMBL10496398 | 0.73 | LMNA (0.37) | KDM4EALDH1A1LMNACNR1ADRA1A | |
| SCHEMBL24177621 | 0.71 | KDM4E (0.40) | KDM4EALDH1A1LMNACNR1ADRA1A | |
| SCHEMBL9511317 | 0.68 | TSHR (0.38) | TDP1 | |
| SCHEMBL20876354 | 0.68 | TSHR (0.38) | TDP1 | |
| SCHEMBL7417972 | 0.68 | TSHR (0.38) | TDP1 | |
| SCHEMBL29012727 | 0.68 | TSHR (0.38) | TDP1 | |
| SCHEMBL10409177 | 0.68 | TSHR (0.38) | TDP1 | |
| SCHEMBL12956362 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023445-A1 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | TEXAS CHILDREN'S HOSPITAL (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023445-A1 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | PSEN1, APP, PHOSPHO1 | KDM4E 3103/4885ALDH1A1 4251/4885LMNA 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.